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Abstract
The present review describes the work carried out during the last 20 years in the field of the
radioprotective activity and toxicity of several classes of organosilicon and organogermanium
compounds (i.e. metallathiazolidines, metalladithioacetals, metallatranes and germathianes).
1. Introduction
During the 20-year period between 1978 and 1998 the Dlgation Gnrale pour
I’Armement and Dpartement de Chimie Pharmacologie, France, sponsored a coordinated
antiradiation drug development program. The objective of this program was to develop a drug or
combination of drugs with organometallated compounds which could be taken by military personnel
or other populations to protect them from the effects of ionizing radiations in a nuclear weapons
attack, medical treatments or, in general, all radiation exposition.
During the research program approximately 562 compounds were chemically synthesized
and tested in mice for their radioprotective properties.
The vast majority of these compounds were metallathiazolidines, metalladithioacetals of N-
substituted cysteamine, methylcysteamine, N-(2-thioethyl)-l,3-diaminopropane, N-substituted
cysteamine or methylcysteamine by naphthylmethylimidazoline and N-substituted
naphthylmethylimidazoline.
120 compounds of these derivatives are characterized by a dose reduction factor (DRF)
between 1.3 and 1.75.
The radioprotective activity and toxicity of several classes of organometallated derivatives
(silathiazolidines, germathiazolidines, siladithioacetals, germadithioacetals, germatranes, silatranes
and germylated sulfides) and their synthesis are reported.
All the biological tests have been performed in the Centre de Recherche du Service de
Sant des Armies, La Tronche, France.
2. Sila- and germathiazolidines
R3
Sila- and germathiazolidines of N-substituted cysteamine, methylcysteamine, N-(2-thioethyl)-
1,3-diaminopropane and N-substituted cysteamine or methylcysteamine by
naphthylmethylimidazoline were prepared according to two methods of heterocyclisation already
described in the literature [1-3].
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Method A
The action of diorganosilicon and-germanium dichloride [3] (in stoichiometric amounts) on N-
substituted cysteamine, methylcysteamine, N-(2-thioethyl)-l,3-diaminopropane and N-substituted
cysteamine or methylcysteamine by naphthylmethylimidazoline in refluxing anhydrous
tetrahydrofuran in the presence of freshly distilled triethylamine gave by a cyclisation reaction, with
elimination of hydrochloric acid from M-CI and SH and NH [4] groups the corresponding products,
Scheme 1.
2 Et3N RI\
R1R2MCI2 + HSCHCH2NH-R4
R2
/
R3
Scheme 1
R3
M
/
+ 2 Et3N.HCi
\N
Method B
The reaction of N-substituted cysteamine, methylcysteamine, N-(2-thioethyl)-l,3-
diaminopropane and N-substituted cysteamine or methylcysteamine by naphthylmethylimidazoline,
in stoichiometric amounts, with the bis(diethylamino)dialkylsilanes or-germanes in anhydrous
tetrahydrofuran resulted in the cleavage of M-N bonds by the NH and SH groups (a transamination
reaction) [1,3-5], forming the corresponding sila- and germathiazolidines in good yields, Scheme 2.
RI\
R1R2M(NEt2)2 + HSCHCH2NH-R4
R2
/
R3
Scheme 2
R3
+ 2 Et2NH
A radioprotective study of metallathiazolidines shows that the silylated and germylated
derivatives have a greater biological activity and a lower toxicity than that of the corresponding
organic compounds [1] (Table I).
3. Sila- and germadithioacetals
R1R2M[S-CH(R3)-CH2R4]2
Sila- and germadithioacetals of N-substituted cysteamine, methylcysteamine, N-(2-thioethyl)-
1,3-diaminopropane, N-substituted cysteamine and methylcysteamine by
naphthylmethylimidazoline and N-substituted naphthylmethylimidazoline were also obtained by two
methods C and D [10].
Method C
The action of diorganosilicon and-germanium dichloride [3] on two equivalents of N-
substituted cysteamine, methylcysteamine, N-(2-thioethyl)-l,3-diaminopropane, N-substituted
cysteamine and methylcysteamine by naphthylmethylimidazoline and N-substituted
naphthylmethylimidazoline in refluxing anhydrous tetrahydrofuran in the presence of freshly
distilled triethylamine gave the acyclic derivatives, Scheme 3.
R1R2MCI2 + 2 HSCHCH2-R4 R1R2M HCH2- + 2 Et3N.HCI
Scheme 3
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Table I- Radioprotective activity of some selected metallathiazolidines
R3
4
Cpd R R2
[Ref.]
1 CH3 C6H5
[1]
R3 R4 LD50
’,mg.kg"1
H H 800
2 CH3 C6H5 CH3 H 750
[1]
3 C2H5 C2H5 H H 1000
[1]
4 CH3 p,CH3C6H4 H H 500
[1]
5 CH3 p-CH3OC6H4 H H 1500
[1]
6 HCI’H2N(CH2)2S HCI:H2N(CH2)2S H
[6]
(c) 600
7 n’C6H13 n-C6H13 H (d) 25,,0
[7]
8 n’C6H13 n-C6H13 CH3 (d) 220
[7]
Injected Irradiation
dose Gy
(m1.k "1 (t, min)a
400 10(15)
400 10 (120)
400 12 (15)
375 10(15)
375 10 (120)
375 12(15)
93.7 10 (15)
500 9.5 (15)
500 9.5 (120)
500
750 9.5 (15)
750 9.5 (120)
750 11.5 (15)
187 9.5 (15)
750 9.5 (15)
750 9.5 (120)
750 11.5 (15)
87 9.5 (15)
,300 7.5 (15)
300 7.5 (90)
300 9.5 (15)
75 7.5(15)
125 8(15)
25 8 (90)
125 10(15)
31.25 8 (15)
110 8(15)
11 0 8 (90)
110 10(15)
27.5 8(15)
a: time between administration of compound and irradiation.
b" dose reduction factor (LD50(30 days)treated/LD50(30 days) untreated).
c: R4 / \ d: R4= N/C’’CH2
O, ?(0H2’3
Survival
rate
%
93
90
70
16
95
0
89
75
80
90
50
90
70
60
0
95
60
50
27
100
50
90
30
100
80
0
0
80
90
0
50
DRFo
1.5
1.4
1.4
1.4
1.6
1.3
1.3
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Cpd R1
[Ref.]
9
[11
10
[11
11
[1]
12
[1]
13
[1]
14
[1]
15
[1]
16
[1]
17
[1]
18
[1]
19
[8]
20
[8]
21
[9]
R2
CH3 C6H5
CH3 C6H5
CH3 p-CH3OC6H4
CH3 p-CH3OC6H4
C6H5 C6H5
n-C4H9 n-C4H9
n-C4H9 n-C4H9
n..C5H11 n-C5H11
n-C5H 11 n-C5H 11
/-C5H 11 kC5H11
CH3 C6H5
i-C5Hll i-CsH11
/-C5H11 kC5H11
R3 R4
’H H
CH3 H
H H
CH3 H
H H
H H
CH3 H
H H
CH3 H
CH3 H
CH3 CH3CO
CH3 CH3CO
H (a)
LD5o
(mg.kg"1
600
5OO
700
600
400
700
300
1000
700
8OO
900
1000
8OO
Injected Irradiation
dose Gy
(mg.kg"1) (t, rain)a
300 9.5 (15)
300 11.5 (15)
300 13.5 (15)
75 9.5 (15)
250 9.5 (15)
250 9.5 (120)
250 11.5 (15)
250 13.5 (15)
250 15.5 (15)
62.5 9.5 (15)
350 9.5 (15)
350 9.5 (120)
350 11.5 (15)
87.5 9.5 (15)
300 9.5 (15)
300 9.5 (120)
300 11.5 (15)
75 9.5 (15)
200 9.5 (15)
200 11.5 (15)
100 9.5 (15)
350 9.5 (15)
350 9.5 (45)
350 11.5 (15)
50 9.5 (15)
1 50 9.5 (90)
150 11.5 (15)
375 9.,5 (15)
500 9.5 (15)
500 9.5 (120)
500 11.5 (15)
125 9.5 (15)
350 9.5 (15)
350 11.5 (15)
87.5 9.5 (15)
400 9.5 (15)
400 9.5 (120)
400 11.5 (15)
400 13.5 (15)
100 9.5 (15)
450 9 (15)
450 9 (120)
450 11 (15)
112.5 9 (5)
500 8.5 (5)
500 8.5 (120)
500 10.5 (15)
25 8.5 (15)
62.5 9(15)
800 7.75 (15)
800 7.75 (90)
Survival DRFb
rate
%
100 1.6
70
40
5O
80 1.75
0
70
70
0
5
100 1.45
20
70
13
95 1.45
20
70
20
90 1.4
30
70
8o -.4
30
70
oo -.4
90
30
80
80 1.4
10
50
20
95 1.4
60
5
94 1.45
22
70
5
0
93 1.35
80
10
50
100 1.35
90
10
80
20
80 1,3
80
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:2:2 n-C6H13 n-C6H13 H (a) 500 750 7.5 (15) 00 1.5
[9] 750 7.5 (90) 90
750 9.5 (15) 0
187 7.5 (15) 40
:2 3 CH3 p-CH3C6H4 H (CH2)2 > 1500 1000 8.25 (15) 70 1.4
[6] CONH2 1000 8.25 (90) 60
000 10.30 (15) 20
2 4 i’C5H11 i’C5H11 H (b) 80 40 8 (15) 50 ’1.33
[7] 40 8 (90) 80
40 10(15) 0
40 10 (90) 20
o 8(5) o
:2 5 n-C6H13 n-C6H13 CH3 H 1500 1000 7.5 (15) 80 1.5
[9] 000 7.5 (90) 90
1000 9.5 /15) 80
:2 6 i’C5Hll i’C5Hll CH3 (b) 150 75 8 (15) 30 1.3
[7] 75 8 (90) 90
75 10(15) 0
75 10 (90) 0
18.75 8(15) 40
:2 7 n’C6H13 n’C6H13 CH3 (b) 200 100 8 (15) 60 ’3
[7] 00 8 (90) 80
100 10(15) 30
25 8(15) 40
a: R4
Method D
The reaction of bis(diethylamino)dialkylsilanes and-germanes with two equivalents of N-
substituted cysteamine, methylcysteamine, N-(2-thioethyl)-l,3-diaminopropane, N-substituted
cysteamine or methylcysteamine by naphthylmethylimidazoline and N-substituted
naphthylmethylimidazoline in anhydrous tetrahydrofuran (a cleavage reaction of M-N bonds by the
SH group) gave the corresponding organometallated derivatives, Scheme 4.
RR2M(NEt2)2 + 2 HSCHCH2-FI4 RR2MCHCH2-R4--I + 2 Et2NH
Scheme 4
4. $ila- and germatrane8
R-M(OCH2CH2)3N
Silatranes and germatranes have been synthesized according to two methods already known
in the literature [13-18].
Method E
This method is the simplest and most general.
The reaction of trimethoxymetallanes, R-M(OMe)3 (M Si, Ge), obtained by the action of
tetramethoxymetallanes [10] with cysteamine, methylcysteamine and N-(2-thioethyl)-l,3-
diaminopropane in the presence of triethanolamine leads to corresponding metallatranes (Scheme
5).
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Table II- Radioprotective activity of some selected metalladithioacetals
R1R2M[S-CH(R3)-CH2R4]2
Cpd
[Ref.]
M=Si
R1 R2 R3 R4 LD50
(mg.kg"1
CH3 CH3 H- NH2 800
2 9 HCI.H2N(CH2)2S HCI.H2N(CH2)2S H (C) 500
[6]
3 0 i-C5Hll i-C5Hll H’ (d) 100
[12]
3 1 n’C6H13 n’C6H13 H (d) 100
[12]
injected Irradiation Survival D"RF
dose Gy (t, min)a rate
(ml.kl"1
400 9.5 (15) 00 1.4
400 9.5 (120) 90
400 11.5 (40) 40
100 9.5 (15) 33
250 7.5 (15) 60 1.3
250 7.5 (90) 0
250 9.5 (15) 20
62.5 7.5 (15) 30
50 7.75 (15) 00 1.4
50 7.75 (90) 80
50 9.75 (15) 0
12.5 7.75 (15) 60
50 7.75 (15) 00 1.5
50 7.75 (90) 00
50 9.75 (15) 0
12.5 7.75 (15) 50
a: time between administration of compound and irradiation.
b: dose reduction factor (LD5o(3o days)treated/LD5o(3o days) untreated).
c:R4= / \ d:R4= N
/
O\ ?(CH2)3-NH
Cpd R1 R2 R3
[Ref.]
3 2 (a) (a) H NH2
[9]
3 3 n’C4H9 n’C4H9 H NH2
[11]
3 4 n’C4H9 n’C4H9 CH3 NH2
[11]
---3 5 i-C5H1 i- iC5Hll H NH2
[11]
3 6 i’C5Hll
[11]
3 7 n-C5H11
[11]
i-C5Hll CH3 NH2
n-C5H11 CH3 NH2
M=Ge
LD5o njected
(mg.kg-ll dose
(mg.kg"1
500 250
250
25O
62.5
600 300
300
400 200
20O
2OO
50
800 400
4O0
4O0
100
600 300
300
800 4o0
400
400
100
Irradiation
Gy
(t, min)a
7.5 (15)
7.5 (9o)
9.5 (15)
7.5(15)
9.5 (15)
9.5 (15)
9.5 (120)
11.5 (15)
9.5 (15)
9.5 (15)
9.5 (120)
11.5 (15)
9.5 (15)
10(15)
12(15)
9.5 (15)
9.5 (120)
11.5 (15)
9.5 (15)
Survival
rate
%
80
70
50
0
100
10
100
90
20
7O
80
5O
6O
3O
100
95
100
50
40
4O
DRFb
1.3
1.3
14
>1.6
1.4
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3 8 CH3
[11]
3 9 CH3
[11]
4 0 /-C5H11
[8]
4 1 /’C5Hll
[9]
4 2 n-C6H13
[9]
4 3 i’C5Hll
[6]
44
[12]
n-C6H13’
#C5Hll
4 6 n’C6H13
[12]
4 7 n-C6H13
[9]
4 8 n’C6H13
[7]
a: R. R2
b: R4
C6H5 CH3 NH2 600
p’CH3"C6H4 CH3 NH2 800
i-C5Hll
i-C5Hll
n-C6H13
i-65Hll
n-C6H13
/-C5Hll
n-C6H13
CH3 qH(CH2)3NH2 300
H (b) 900
H (b) 800
H ’4H(CH2)2CONH2 > 1500
H ’IH(CH2)2CONH2 > 1500
H (c) 80
H (c) 150
n’C6Hi3 CH3 NH2 800
n’C6H13
/ \
O.__jN(CH2)3-NH
CH3 (d) 160
3OO
3O0
3OO
75
400
400
400
100
150
150
150
37.5
450
450
450
112.5
40O
400
400
100
1000
1000
1000
lOOO
1000
50
50
50
5O
50
50
12.5
75
75
75
18.75
800
800
800
80
80
80
80
20
C: R4 N
/
9.5 (15) 90 > 1.5
9.5 (120) 20
11.5 (15) 90
9.5 (15) 45
9.5 (15) 85 1.5
9.5 (120) 70
11.5 (15) 60
9.5 (15) 33
9(15) 87 1.4
9 (120) 40
11 (15) 40
9 (15) 90
7.75 (15) 50 1.3
7.75 (90) 80
9.75 (15) 0
7.75 (15) 50
7.5 (15) 00 1.5
7.5 (90) 80
9.5 (15) 0
7.5(15) 50
8.25 (15) 00 1.4
8.25 (90) 90
10.25 (15) 30
8.25 (15) 90 1.3
8.25 (90) 20
7.75 (15) 00 1.7
7.75 (90) 00
7.75 (180) 90
9.75 (15) 70
9.75 (90) 0
11.75 (15) 30
7.75 (15) 80
7.75 (15) 90 1.4
7.75 (90) 00
9.75 (15) 0
7.75 (15) 70
7.5 (15) 00 >1.6
7.5 (90) 70
9.5 (5) 90
8 (15) 60 1.3
8 (90) O0
o (5) o
10 (90) 0
8(15) 50
d’R4=
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M(OMe)4 + R-H
MeOH RM(OMe)3
N(CH2CH2OH)3
3 MeOH R-M(OCH2CH2)3N
Scheme 5
Method F
The second method of synthesis of silatranes and germatranes includes of
methoxymetallatranes. Thus, methoxymetallatranes obtained by the reaction of
tetramethoxymetallanes with triethanolamine gave a condensation reaction with cysteamine,
methylcysteamine and N-(2-thioethyl)-1,3-diaminopropane affording the metallatranes (Scheme 6).
M(OMe)4 + N(CH2CH2OH)3
3 MeOH MeOM(OCH2CH2)3N
R-H --
R-M(OCH2CH2)3N MeOH
M Si, Ge; R -SCHCH2NH2.HCI,-S(CH2)2NH(CH2)3NH2.HCI; R’= H, CH3
R’
Scheme 6
Table III- Radioprotective activity of some selected metallatranes
YHN-CH2-CH(R)-SM(OCH2CH2)3N
Cpd M R Y
[Ref.]
4 9 Si H H.HCl
[lO]
,5 0 Ge H H.HCI
[10]
5 1 Ge H H2N(CH2)3
[lO]
,5 2 Ge H 2 HCI.H2N(CH2)3
[lO]
LD5o Injected Irradiation
(mg.kg "1) dose Gy
(mg.kg "1) (t, min)a
600 300 9.75 (15)
300 11.75 (15)
75 9.75 (15)
700 350 9.75 (15)
350 9.75 (120)
350 11.75 (15)
87.5 9.75 (15)
300 50 9.5 (15)
50 9.5 (120)
50
37.5 9.5(15)
900 450 9.5 (15)
450 9.5 (120)
450 11.5 (15)
112.5 9.5(15)
1500 1000 10 (15)
1000 10 (120)
1000 12 (15)
5 3 Ge CH3 H.HCI
Survival DRFb
rate
%
80 1.3
10
40
80 1.4
0
40
0
60 1.4
0
40
10
100 1.45
20
30
70
80
0
70
5. Germylated sulfides
{[HC I.H2NCH2-CH(R)-S]2GeS}3
Table IV Rad
Cpd
[Ref.]
54
[9]
[10]
ioprotective activity of germylated sulfides
R LD5o Injected Irradiation
H
(mg.kg"1)
1000 CH3
8OO
dose
(m1.k"1)
5OO
5O0
5OO
125
800
8OO
Gy (t, min)a
7.5 (15)
7.5 (90)
9.5 (15)
7.5 (15)
9.5 (15)
Survival rate DRFb
%
O0 .’6
50
80
10
O0 > 1.5
90
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The syntheses of these compounds were realized by the action of NaSH on
{[HCI.H2NCH2CH(R)]2SGeCI2 (R H, CH3) [10] in anhydrous pyridine, Scheme 7.
[CI.H2NCH2CH(R)S-]GeCI2.2 NaSH
2 NaCllpyridine
Scheme 7
6. Diisoamyldithiagermocane
(i-C5H12)2Ge(SCH2CH2)2S
This compound was obtained by the reaction of 2,2’-thiodiethanethiol with
diisoamylgermyldichloride [3], in equimolar amount, in anhydrous tetrahydrofuran and in the
presence of freshly distilled triethylamine, Scheme 8.
2 Et3N (/-C5HI)2GeCI2 + (HSCH2CH2)2S m (i-CsH11)2Ge(SCH2CH2)2S + 2 Et3N.HCI
Scheme 8
Table V- Radioprotective activity of diisoamyldithiagermocane
Cpd LD5o Injected Irradiation Survival rate
[Ref.] (mg.kg"1) dose Gy (t, min)a %
(mg.kg "1)
5 6 >1500 1000 7.5 (15) 60
[6] 1000 7.5 (90) 50
250 7.5 (15) 60
DRFb
7- Di-n-hexylpyridinooxathiagermolane
(n-C6H 13)2G)
s
This product was prepared by action of dichlorodi-n-hexylgermanium [3] on 2-thio-3-pyridinol
in refluxing anhydrous tetrahydrofuran in the presence of freshly distilled triethylamine, Scheme 9.
HO
THF (n-C6H3)2GeCI2 +
HS
2 Et3N
Scheme 9
+ 2 Et3N.HCI
8. Pharmacology: evaluation of radioprotection
Male CD1 mice (Charles River, France), 25 g body weight, were used. The compounds were
injected intraperitoneally 15, 90, 120 or 180 rain before irradiation. The irradiation dose was
LD100/30 days for untreated mice (7.5, 7.75, 8, 8.25 or 8.3 Gy, according to the irradiation date) or a
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2 Gy greater dose. When necessary, other irradiation doses (between 8.5-13.5 Gy were tested in
order to evaluate the irradiation LD50/30 days of protected mice. The injected dose of the
compound was equal to one-half or one-eighth of the LD50 value which had been determined
previously. The radioprotective effect was evaluated by the Dose Reduction Factor (DRF), which is
the ratio between the LD50/30 days of treated mice and that of control mice (between 6.5 and 6.75
Gy, according to the date).
Table VI- Radioprotective
Cpd LDso
[Ref.] (mg.kg "1)
5 7 800
[6]
activity of d
Injected
dose
Img.k "1
400
400
400
100
-n-hexylpyridino
Irradiation
Gy (t, min)a
7.5 (15)
7.5 (90)
9.5 (15)
7.5 (15)
oxathiagermolane
Survival rate DRFb
%
40
50
0
20
Irradiation was applied using a cobalt-60 source at the dose rate of 0.3-0.4 Gy.min-1 according
to the date. During irradiation, animals were placed in a Plexiglass box with 30 cells in a
homogeneous field, 28.5 x 28.5 cm in area. Dosimetry was checked with an ionisation chamber
dosimeter. The different LD5o values were determined by probit analysis.
9. Conclusion
The objective of this work was to incorporate potentially radioprotective organic groups in
organometallic structures such as metallathiazolidines, metalladithioacetals, metallatranes and
germathianes so as to decrease their toxicity and increase their radioprotective activity.
Tables through Vl summarize the radiation protection obtained in mice after intraperitoneal
administration in miglyol solution of the organosilylated and organogermylated derivatives
described. Generally, these organometallic compounds have a lower toxicity and a radioprotective
activity equal to or greater than that of the starting organic derivatives (namely cysteamine [19],
methylcysteamine [10] and N-substituted cysteamine or methylcysteamine [6, 9] and N-substituted
naphthylmethylimidazoline [7, 12]). We have to underline that in some cases this great
radioprotective activity was obtained with organosilylated or organogermylated derivatives injected
in lower doses, expressed in mmol fraction, than those used for starting organic compounds.
The analysis of the toxicity and powerful radioprotective effect of all compounds presented in
Table shows that the metallathiazolidines have generally a good radioprotective activity and lower
toxicity compared with starting organic derivatives.
Several compounds in this series (1, 2, 6, 9 and 10) exhibit a dose reduction factor (DRF) of
1.5-1.75.
The LD50 dose of each compound indicated that they were weakly toxic (500-1500 mg.kg-1).
-Derivative 1 (DRF 1.6; LD5o 800 mg.kg-1) at one-half of LD5o (the maximum tolerated
dose, MTD) this product protects 93 % and 90 % of mice at 10 Gy 15 or 120 minutes after injection
and 70 % survival at 12 Gy 15 minutes before irradiation. At one-eighth of the LD5o, there was a 16
% survival at a dose of 10 Gy.
-Derivative 2 (DRF 1.5; LD50 750 mg.kg-1) at one-half of LD5o 95 % and 89 % protection
were obtained at doses of 10 and 12 Gy. At one-eighth of the LD5o, there was still 75 % survival at a
dose of 10 Gy.
-Derivative 6 (DRF 1.6; LD50 600 mg.kg-1) at one-half of LDs0 100 % and 90 % survival
were obtained at doses of 7.5 and 9.5 Gy and 50 % survival was observed at a dose of 7.5 Gy. At
one-eighth of the LD5o, there was a 30 % survival at a dose of 7.5 Gy.
-Derivative 9 (DRF 1.6; LD50 600 mg.kg) at one-half of LD5o 100 %, 70 % and 40 %
survival were obtained at doses of 9.5, 11.5 and 13.5 Gy. At one-eighth of the LD5o, there was a 50
% survival at a dose of 9.5 Gy.
-Derivative 10 (DRF 1.75; LD50 500 mg.kg-1) at one-half of LD5o 80 %, 70 % and 70 %
survival were obtained at doses of 9.5, 11.5 and 13.5 Gy.
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The analysis of the results reported in Table II shows that the siladithioacetals and
germadithioacetals 31, 36, 38, 39, 42, 4,5 and 47 have an important radioprotective activity (DRF
between 1.5-1.7).
-Derivative 31 (DRF 1.5; LD5o 100 mg.kg-1) at one-half of LD5o 100 % protection was
observed at a dose of 7.75 Gy. At one-eighth of the LD5o, there was still 50 % survival at a dose of
7.75 Gy.
-Derivative 36 (DRF>1.6; LD5o 600 mg.kg-) at one-half of LD5o 100 % and 95 % survival
were obtained at doses of 10 and 12 Gy.
-Derivative 38 (DRF>1.5; LD5o 600 mg.kg-1) at one-half of LD5o 90 % survival was observed
at doses of 9.5 or 11.5 Gy. At one-eighth of the LD5o, there was 45 % survival at a dose of 9.5 Gy.
-Derivative 39 (DRF 1.5; LD5o 800 mg.kg"1) at one-half of LD5o 85 %, 70 % and 60 %
survival were obtained at doses of 9.5 and 11.5 Gy. At one-eighth of the LD5o, there was 33 %
survival at a dose of 9.5 Gy.
-Derivative 42 (DRF 1.5; LD5o 800 mg.kg-1) at one-half of LD5o 100 % and 80 % survival
were observed at a dose of 7.5 Gy. At one-eighth of the LD50, there was still 50 % survival at a dose
of 7.5 Gy.
-Derivative 45 (DRF 1.7; LD5o 80 mg.kg-1) at LD5o/1.6 100 % and 90 % survival were
observed at a dose of 7.75 Gy. 70 % and 30 % survival were also obtained at doses of 9.75 and
11.75 Gy. At LD5o/6.4, there was still 80 % survival at dose of 7.75 Gy.
-Derivative 47 (DRF>1.6; LD5o 800 mg.kg-1) the administration of this product at of LD5o
protects 100 % and 70 % of mice at a dose of 7.5 Gy and 90 % survival was obtained at a dose of 9.5
Gy.
At last, it is important to note the significant radioprotective activity of organogermylated
sulfides 54 and 55 (DRF 1.5-1.6).
-Derivative ,54 (DRF 1.6; LD5o 1000 mg.kg-) at the MTD this product protects 100 % and
80 % of mice at doses of 7.5 and 9.5 Gy, it also protects 50 % of mice at a dose of 7.5 Gy.
-Derivative .5,5 (DRF 1.5; LD5o 800 mg.kg-1) at of LD50 100 % and 90 % protection were
observed at doses of 9.5 and 11.5 Gy.
In short, several organosilylated and organogermylated compounds present a good
radioprotective activity compared with the starting organic derivatives due to the presence in these
molecules of organometallic groups which increase the hydrosolubility and by the presence of
organic ligands which increase the liposolubility and biological activity of these molecules, thereby
favouring their passage through the cellular membranes.
The results presented in this paper confirm the positive contribution of germanium and silicon
in this field in agreement with previous works [1, 6-12, 20-22] and the interesting biological activity
of organosilicon and organogermanium compounds in different fields [23-44].
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